EU Delays For Portola As CHMP Trend Votes Go Good And Bad

Portola will have to rein in its European sales ambitions as the CHMP gives early verdicts on its Factor Xa inhibitor betrixaban and its reversal agent andexanet. 

Clock
Delays for Portola's products • Source: Shutterstock

Portola Pharmaceuticals Inc.'s Factor Xa inhibitor betrixaban's future in the EU is looking dicey after the EMA's CHMP issued a negative trend vote on the product's marketing application at its meeting this week. On the plus side, it also communicated a positive trend vote on the MAA for its universal Factor Xa inhibitor reversal agent, AndexXa (andexanet alfa), but this too represents a slight delay.

Betrixaban's negative trend vote means it is unlikely the committee will adopt a positive opinion on the company's MAA at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip